Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086203 · ClinicalTrials.gov registry record · Phase 2
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study of Chronic Lymphocytic Leukemia, sponsored by Point Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Study locations
NCT00086203 is a Phase 2 study of Chronic Lymphocytic Leukemia that has completed, run by Point Therapeutics. The trial reports 19 study locations across 12 states.
The verdict
NCT00086203, a Phase 2 study of Chronic Lymphocytic Leukemia, has completed, sponsored by Point Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19
- Study locations
Study Summary
The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Talabostat mesylate (PT-100) tablets
Study Locations (19)
New York
- Queens Medical Associates, PC - Fresh Meadows
- Long Island Jewish Medical Center - New Hyde Park
- NYU Medical Center - New York
- James P. Wilmot Cancer Center/University of Rochester - Rochester
Florida
- Ocala Oncology Center - Ocala
- Gulfcoast Oncology Associates - St. Petersburg
North Carolina
- Raleigh Hematology/Oncology Clinic - Cary
- Wake Forest University Health Sciences - Winston-Salem
Oklahoma
- Cancer Care Associates/Oklahoma City - Oklahoma City
- Cancer Care Associates--Tulsa - Tulsa
Texas
- Texas Cancer Center/Abilene - Abilene
- MD Anderson Cancer Center - Houston
Arkansas
- University of Arkansas for Medical Science - Little Rock
Indiana
- Indiana Oncology/Hematology Consultants - Indianapolis
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086203
The ClinicalTrials.gov registry entry for NCT00086203 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Point Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT00086203 reports 19 study locations spanning 12 distinct geographic areas - top geographies include New York, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00086203 about?
NCT00086203 is a clinical study titled "Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)". The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.
What is the current status of trial NCT00086203?
This trial is currently completed. It is a Phase 2 study. Estimated completion is 2007-09.
What conditions does trial NCT00086203 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT00086203?
The interventions under investigation include: Rituximab (DRUG), Talabostat mesylate (PT-100) tablets (DRUG).
Who is sponsoring clinical trial NCT00086203?
This trial is sponsored by Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00086203 being conducted?
This trial has 19 study locations across Arkansas, Florida, Indiana, Massachusetts, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
-
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
RECRUITING · Phase 2
-
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
RECRUITING · Phase 2
-
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.